In plain terms: 40Hz Gamma Sensory Stimulation shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
40Hz Gamma Sensory Stimulation
The evidence as the record states it
Ang et al. (Translational Psychiatry, 2025; PMID 41381439): systematic review and meta-analysis of gamma-frequency auditory and visual stimulation in Alzheimer's disease and mild cognitive impairment, 11 controlled trials, 341 participants; publicly funded in China. The largest sham-controlled trial, OVERTURE (Hajós et al., Front Neurol, 2024; PMID 38515445, n=74), missed its primary clinical outcome, and the structural MRI finding that drives the positive imaging endpoint (Da et al., J Alzheimers Dis, 2024; PMID 38073386) came from the same trial. Both papers state funding by Cognito Therapeutics, maker of the device, and most of their authors are Cognito employees with stock options and patent applications assigned to the company. Grade C reflects null cognitive and functional endpoints against a positive imaging endpoint that has been reported only by the device maker's own staff, high heterogeneity, and a tinnitus safety signal. A second 2025 meta-analysis, Wu et al. (Neurorehabil Neural Repair, 2025; PMID 40855942), reports large cognitive gains across 8 trials, but it pools transcranial electrical and magnetic brain stimulation with sensory stimulation, so it does not grade this modality and is not relied on here.
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What this grade covers and what it does not
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.